Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1988-9-7
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0012-6667
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35 Suppl 2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
214-5
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3396484-Adult,
pubmed-meshheading:3396484-Aged,
pubmed-meshheading:3396484-Cefotaxime,
pubmed-meshheading:3396484-Female,
pubmed-meshheading:3396484-Half-Life,
pubmed-meshheading:3396484-Humans,
pubmed-meshheading:3396484-Male,
pubmed-meshheading:3396484-Middle Aged,
pubmed-meshheading:3396484-Respiratory Tract Infections
|
pubmed:year |
1988
|
pubmed:articleTitle |
The value of twice-daily cefotaxime in lower respiratory tract infections.
|
pubmed:affiliation |
1st Pathological Clinic, General Hospital of Athens.
|
pubmed:publicationType |
Journal Article
|